Antitrust Law

FTC Preserves Status Quo in Long-Term Care Pharmacy Market

, The Legal Intelligencer

   | 0 Comments

Omnicare Inc.'s eight-month pursuit of acquiring PharMerica Corp. finally crumbled recently under the weight of the Federal Trade Commission's lawsuit. If successful, Omnicare's post-acquisition market share would have been 57 percent of the long-term care pharmacy (LTC pharmacy) market. The FTC stepped in to stop what it believed would have been a resulting anti-competitive advantage that would hurt the health care market, its patients and the taxpayers "who foot much of the bill under Medicare."

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to LexisAdvance®.

Continue to LexisAdvance®

Not a LexisAdvance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via LexisAdvance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at customercare@alm.com

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202544341747

Thank you!

This article's comments will be reviewed.